Their mechanism of action involves one Fab binding to a specific tumor ... ACROBiosystems TCE bispecific antibodies offer substantial advantages over standard IgG monoclonal antibodies. Traditional ...

Calico will leverage 9MW3811’s anti-inflammatory mechanism to advance its mission of addressing aging-related diseases.

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is ...

Traditional and new laboratory tools along with advances in AI are outlining a new paradigm in human disease modeling.

WILMINGTON, Del., June 03, 2025--Multiple Incyte Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted at EHA 2025 ...

Use of an investigational monoclonal antibody called bimagrumab added to semaglutide produced weight loss while preserving ...

Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...

Verekitug is a novel recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to the TSLP receptor and inhibits proinflammatory signaling initiated by TSLP.

Cidara Therapeutics has reported encouraging top-line outcomes from the Phase IIb NAVIGATE trial of the investigational ...

GS-1811, a potential first-in-class immunotherapy, is designed to target and deplete immunosuppressive Tregs in the tumor ...

Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody (mAb) to TuHURA's late-stage immuno-oncology pipeline TuHURA planning to initiate a Phase ...